The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 28 April 2026•Updated 29 April 2026•

1 min read

Pfizer Bolsters Portfolio with Positive ELREXFIO Trial Results and VYNDAMAX Settlements

Key Facts

1Pfizer entered into settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla Ltd regarding patent infringement lawsuits.

2The settlements relate to patents for VYNDAMAX, a treatment for cardiomyopathy transthyretin-mediated amyloidosis.

about 1 month ago

Version History

Version 3about 1 month ago

What changed: The story was updated to include successful Phase 3 trial results for the oncology drug ELREXFIO alongside the previous patent settlements.

Version 2about 1 month ago

What changed: The story was updated to confirm the formal dismissal of the lawsuit and the conclusion of the trial against Hikma Pharmaceuticals following the first day of proceedings.

Version 1about 1 month ago

What changed: The story was updated to include the specific patent expiration date (June 1, 2031) and the expected impact on revenue stability through mid-2031.

Pfizer Inc. has achieved a dual strategic milestone across its oncology and specialty medicine portfolios. The company announced positive topline results from the Phase 3 MagnetisMM-5 study of ELREXFIO for relapsed or refractory multiple myeloma, demonstrating a statistically significant improvement in progression-free survival (PFS). Simultaneously, Pfizer finalized settlement agreements with Hikma Pharmaceuticals, Cipla Ltd, and Dexcel Pharma to resolve patent litigation for its drug VYNDAMAX. These settlements effectively extend U.S. patent protection until June 1, 2031, successfully delaying generic competition for the cardiomyopathy treatment. By combining successful clinical breakthroughs with robust intellectual property protection, Pfizer secures vital revenue streams and reinforces its long-term financial stability. These developments provide significant operational clarity for the pharmaceutical giant moving forward.